PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
108.24%
G&A change of 108.24% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-3.86%
Operating expenses reduction while Biotechnology median is 4.34%. Seth Klarman would investigate advantages.
-3.86%
Total costs reduction while Biotechnology median is 3.07%. Seth Klarman would investigate advantages.
-100.00%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-1.12%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
-1.49%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
3.86%
Operating income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
-73.89%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-1.47%
Pre-tax income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-1.47%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
12.77%
EPS change of 12.77% versus flat Biotechnology. Walter Schloss would verify quality.
13.49%
Diluted EPS change of 13.49% versus flat Biotechnology. Walter Schloss would verify quality.
16.41%
Share count change of 16.41% versus stable Biotechnology. Walter Schloss would verify approach.
17.29%
Diluted share change of 17.29% versus stable Biotechnology. Walter Schloss would verify approach.